1. Introduction
Background
The most complex and rapidlyevolvingclass of biological macromolecules appear to be glycan chains, which coat virtually all cell surfaces in nature, [1] display remarkable diversity in length, order,l inkaget ype, modificationsa nd branching structure, and have numerous biological roles. [2] This review focuses on ah uman changei ns ialic acids, which are af amilyo fn inecarbon backbone acidic monosaccharides that commonly terminate the glycan chains of the animals of the deuterostome lineage, as well as some successful bacterial pathogens of deuterostomes. [3] In mammals, there are % 10 6 -10 8 sialic acids present on each cell of all major tissues, prominently composed of N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc; Scheme 1). [4] [5] [6] [7] [8] [9] This review focuses on the human loss of Neu5Gc, which differs from the precursor sialic acid Neu5Ac throught he enzymatic addition of ah ydroxy group to the N-acetyl moiety at C-5. [10, 11] 
Discovery of Sialic Acids
In 1935, Ernst Klenk discovered gangliosidesi nt he brain tissue of ap atient with Niemann-Pick's disease, [12, 13] and in 1941 he described an acid-hydrolyzed carbohydrate component that he named "neuraminicacid". [14] Meanwhile in 1936, Gunnar Blix independently reported that acid hydrolysis combined with fractionation of bovine submaxillary mucin resulted in the formation of crystalso fa nu nknown sugar, [12, 15] which he did not name "sialic acid" until 1952. [16] Ultimately it was confirmed that Blix and Klenk wered escribing the same familyo f sugars [17] and in 1957 Blix, Klenk, and Gottschalk (who was studying influenza virus receptors) all agreedt o" avoid further confusion" by officially calling them sialic acids. [18] Nonetheless, the two namesh ave persisted to this day. [19] More than 50 types of sialic acids originating from the two "primary sialic acid backbones" (Neu5Aca nd Kdn) have now been described in nature, [20, 21] but the two most prevalent in mammals are Neu5Acand Neu5Gc. [10, 22] 
Werner Reutter's Major Contributions to Sialic Acid Biology
This issue is dedicated to the memory of Professor Werner Reutter,apioneer in the study of sialic acids. After reporting the famous d-galactosamine study, [23] Reutter and colleagues began making key contributionst ot he field of sialic acid biology by studying the biosynthesis [24] and half-life of Neu5Ac in normal,c ancerous (hepatomas), regenerating, and neonatal livers. [25, 26] After discovering that UDP-GlcNAc 2-epimerase (GNE),akey enzyme in sialic acid biosynthesis, was downregulated in hepatomas compared to normall ivers, [24] they cloned and characterized its activity and reported it to be abifunctional enzyme having both UDP-GlcNAc 2'-epimerase and ManNAc kinase activity. [27] GNE was subsequently discovered to be the About 2-3 milliony ears ago, Alu-mediated deletion of ac ritical exon in the CMAH gene becamef ixed in the hominin lineage ancestral to humans,p ossibly through as tepwise process of selection by pathogen targeting of the CMAHp roduct (the sialic acid Neu5Gc), followed by reproductive isolation through female anti-Neu5Gca ntibodies.L oss of CMAH has occurredi ndependently in some other lineages, but is functionally intact in Old World primates, including our closest relatives, the chimpanzee. Although the biophysical and biochemical ramifications of losing tens of millions of Neu5Gc hydroxy groups at most cell surfaces remains poorly understood, we do know that there are multiscale effects functionally relevant to both sides of the host-pathogen interface. Hominin CMAH loss might also contribute to understanding humane volution, at the time when our ancestors were starting to use stone tools, increasing their consumption of meat, andp ossibly hunting.
Comparisons with chimpanzees within ethical and practical limitations have revealed some consequences of human CMAH loss, but more has been learnedb yu sing am ouse model with ah uman-like Cmah inactivation. For example, such mice can develop antibodies against Neu5Gc that could affect inflammatory processes like cancer progression in the face of Neu5Gc metabolic incorporation from red meats, display ah yper-reactive immune system,ahuman-like tendencyf or delayed wound healing, late-onset hearing loss, insulinr esistance, susceptibility to muscular dystrophyp athologies,a nd increased sensitivity to multiple human-adapted pathogens involving sialic acids. Further studies in such mice could provide am odel for other human-specific processes and pathologies involving sialic acid biology that have yet to be explored.
gene mutated in inclusion body myopathy 2, [28] the most commonh ereditaryi nclusionb ody myopathy affecting humans. [29] Simultaneously,R eutter's group revolutionized the field of metabolic sialic acid glycoengineering when they discovered that adding 2-deoxy-2-propionamido-d-mannose (ManNProp) or,t oalesser degree, 2-deoxy-2-propionamido-d-glucose (GlcNProp) to liver homogenates resulted in the biosynthesis of N-propylneuraminic acid( NeuProp), ac ompletely unnatural sialic acid that retained the propyl group from its modified metabolic precursors. [30] As eries of subsequents tudies by Reutter,B ertozzi and others revealed that modified metabolic precursors (particularly modified mannosamines)c ould be incorporated as modified sialic acids ontoc ell surfacesa satool for understanding biological relevance. [31] 2. N-Glycolylneuraminic Acid (Neu5Gc), a Common Sialic Acid
HistoryofM edical Primatology and Genomics
Over ac enturya go at the Pasteur Institute in France, Dr. Élie Metchnikoff and Dr.P ierre Paul Émile Roux combined their Madrid Medical Congress and Ifla-Oziris awardst op urchase ac ohorto fc himpanzees and successfully developed the first animal model for an infection affecting over 10 %o ft he human population in Paris at the time:s yphilis. [32] Metchnikoff and his colleague Besredka subsequently developed the first non-human primatem odel for studying typhoid/enteric fever [33] and together,t his pioneering work strongly contributed to the modern era of medical primatology. [32] Many years later,t he introductiono fp rotein and nucleic acid sequencing revealed the remarkable genetics imilarityo fh umans and chimpanzees, eventually leadingt ot he famous hypothesis of King and Wilson, that "their macromolecules are so alike that regulatory mutations might account for their biological differences". [34] It took more than 20 years for the first clear-cut exception to this hypothesis to be discovery,t he selective absence of Neu5Gc in humans, [35] which was shown to be due to an inactivating exon deletion in CMP-Neu5Ac hydroxylase (CMAH) that became fixed in the Homo lineage sometime after the divergence from chimpanzees. [36, 37] This and subsequently discovered genetic and biomedical differences [38] motivated the initial sequencing of the chimpanzee genome [39] and ongoing sequencing of other non-human primateg enomes with the aim of determining genetic components specifically accounting for these differences in phenotypes.
[40] To day we also know that, despite our genetics imilarity with other primates,t here are specifici nfections andd iseases that primarily affect humans,a nd some cannot be adequately modeled in non-human primates. [41] Some of those that involve sialic acid biologya re discussed furtherbelow.
Sialic Acid Biosynthesis
In mammals, sialic acids are produced through the hexosamine biosynthesis pathway (HBP), which is rate limited by the conversion of fructose-6-phosphate to glucosamine-6-phosphate by glutaminef ructose-6-phosphate amidotransferase (GFAT). AlthoughG FATonly utilizes 1-5 %o ft otal glucose, dysregulation of this pathway has been implicated in multiple metabolic diseases,s uch as diabetes, Alzheimer's, cardiovascular disease, and some cancers. [42] In the final steps of sialic acid biosynthesis, the primary sialic acids of vertebrates (Neu5Aca nd Kdn) are formed by the condensation of ManNAc-6-P (Neu5Ac) or Man-6-P (Kdn) with phosphoenolpyruvate (PEP). Neu5Ac can then be further modified at C-5 or be further modified at C-4, C-7, C-8, and/or C-9 to generate over 50 differentf orms of sialic acid. [5, 21, 43] In relation to glycan biosynthesis in deuterostomes, sialic acids are unique in that they require am onophosphate nucleotide donor (CMP) for activation [44] and must travel to the nucleus in order to be activated into their CMPconjugated form.
[45] Cytosolic CMP-conjugated Neu5Gci st hen produced by the hydroxylationo fC MP-Neu5Ac by CMAH, the only enzyme known to be ablet ob iosynthesize Neu5Gc from Neu5Ac in any living species. [4, 6, 8, 9, 46] 
Human-Specific Loss of Neu5Gc Expression
Given their high abundance in animal tissues,i ti sh ardly surprisingt hat Neu5Gca nd other structural variants of Neu5Ac had already been identified and characterized by the time the term "sialic acid" was officially agreedu pon in the 1950s. [18] Ajit Varki is aphysician/scientist who is Distinguished Professor of Medicine and Cellular and Molecular Medicine, co-director of the Glycobiology Research and Training Center at the University of California, San Diego (UCSD), and co-director of the UCSD/Salk Center or Academic Research and Training in Anthropogeny (CARTA). He is also executive editor of the textbook Essentials of Glycobiology and is an elected member of the National Academy of Medicine and the American Academy of Arts and Sciences.
Subsequently,i tw as reported that CMAH was the hydroxylase/ mono-oxygenase that converted the sugar nucleotide CMPNeu5Act oC MP-Neu5Gc in ac omplex mechanism requiring av ariety of co-factors, including cytochrome b5/b5 reductase, iron, oxygen, and NADH. [9] Although humans hadl ong been known to lack easily detectable levelso fN eu5Gc compared to other mammals, the inability of humans to synthesize Neu5Gc was not immediatelya pparent because small amounts of this sialic acid, particularly on tumors and fetal tissues, were reported by using antibodies. [47] [48] [49] [50] [51] It was later shown that Neu5Gc in humans is incorporated from dietarys ources and presentedo n some epithelial and endothelial cell surfaces. [52] [53] [54] [55] In 1982, Roland Schauer noted that, despite reports of the presence of Neu5Gci nt issues, Neu5Gc production wasm issing in humans, possibly antigenic, and potentially contributing to several pathological states, [22] including "serum sickness" in human patients receivingi nfusions of animal sera.
[56] Sixteen years later, two groups independently discovered that humans lack afunctional CMAH enzyme and are therefore incapable of endogenous Neu5Gc production. [35] [36] [37] Both groups reported agenomic mutationt hat eliminated a9 2bpe xon in CMAH. While one report predicted the existence of al argef rame-shifted inactive protein, [36] the other correctly showedt hat the frame-shift resulted in as mall, truncated, inactive protein [37] (see also below).T he ramificationso fN eu5Gcl oss continue to be explored. [54, 55, 57, 58] 
Geneticbasis of human-specific loss of Neu5Gc expression
The human 478 bp region of genomic DNA deletioni nC MAH, including the 92 bp exon, was later shownt ob ed ue to an Alu-Aluf usion that eliminated the sequences encoding the Rieske iron-sulfur-binding region,w hich is essential for its enzymatica ctivity. [59] [60] [61] Comparative genomic analysis revealed that chimpanzees, bonobos, gorillas, orangutans, gibbons, baboons, and rhesus monkeys all contain an ancient AluSq retroposon [62] (subsequently designated sahAluSq) % 350 bp downstream from the human deletion site. [59] Although severalo ther Alu elements were found in common between humans and primates, humans uniquely contain an AluY elementa rising from the fusion (subsequently designated sahAluY) that replaced both the sahAluSq and the missing 92 bp exon. Thus, sahAluY-mediated deletion of the genomic DNA (478 bp), including the 92 bp exon and intron fusion was proposed as the model forhuman CMAH inactivation. [59] 3.2. Timing of CMAH loss in the homininlineage Although technical limitations have prevented precise biochemicald ating of CMAH pseudogenization in the hominin fossil record, [60, 63] multiple genomic methods (see below) deduced that homininC MAH loss likely occurred about 2-3 million years ago (Ma) , during the biomechanical and immunological period of transition of early hominins from forests to open savannahs. [64] [65] [66] [67] [68] Although technically challenging, biochemical methods were developedt os uccessfully extract sialic acids from some Homo neanderthalensis fossils, [60] and the lack of detectableNeu5Gc in these bones confirmed that CMAH inactivation occurred before the last common ancestor between Homo sapiens and H. neanderthalensis approximately 500 000 years ago. [60] CMAH inactivation has since been independently confirmed genetically by analyzing the limited Neanderthal and Denisovan genomic information that has become available. [69] Unfortunately,t he same biochemical methods originally used by our group on H. neanderthalensis fossils failed to obtain ad etectable amount of sialic acid from Homo erectus fossils, [70] which likely decayed more rapidlyi ns ubtropical or tropical climates. [71] Therefore, three independent genomic methodsw ere employed to approximate hominin CMAH loss. [60, 61] First, the timing of human Alu-mediated exon deletion based upon Alu sequence analysis approximated that CMAH inactivation occurred2 .7 AE 1.1 Ma. Second, molecular clock analysis of the CMAH pseudogene( CMAHP)b ased on the substitution rate at nonsynonymous sites versuss ynonymous sites estimated that CMAH inactivation took place 2.8 Ma. [60] However, these estimations were based upon the divergence of humans and chimpanzees taking place % 5.3 Ma, which was subsequently estimated to have occurred % 6Ma, [72] and the estimation of CMAH inactivationw as changed to 3.2 Ma.
[61] Finally,g enealogical analysiso fh aplotypes under significant linkage disequilibrium on a7 .3 kb CMAH intronic regionw as carried out on 132 chromosomes from 18 human populations worldwide, and the most common recent ancestor was approximated at 2.9 AE 0.5 Ma. [61] In summary,a ll three genomic approximations performed on CMAH placed the initial hominin CMAH loss in the era of the australopithecines [64, 73] and just prior to the emergence of genus Homo.
General evolutionary implications
The placement of hominin CMAH inactivation % 3Mac oincides with major evolutionary changes in hominins transitioning from forests to open savannahs, including biomechanical adaptation towards fully striding bipedalism, [68, 74] increased consumption of other animals( expansion of prey base), [75, 76] increasedb ody and brain size, [77] and the earliest developments of Oldowan stone tool use. [66, 76, 78, 79] 4. Proposed Mechanisms for Selection and Fixation of the Human CMAH Pseudogene
Pathogen-mediated selectivepressures
Many pathogens bind, synthesize, and/or utilize host sialic acids as am echanism of survival or virulence, [80] [81] [82] [83] and many deadly human pathogens such as human influenza, [84] [85] [86] Salmonellat yphi, [87] and Plasmodium falciparum [88] [89] [90] prefer Neu5Aco ver Neu5Gc. Moreover, most of the pathogenic and viral sialic-acid-cleaving enzymes (sialidases/neuraminidases) studied prefer Neu5Ac over Neu5Gc substrates; [91] this could increases usceptibility for many infections.
Conversely,s everalp athogens have ab inding preference for Neu5Gc, [92, 93] including Plasmodium reichenowi,aclose relative of P. falciparum that primarilyi nfects chimpanzees. [90] P. reichenowi and P. falciparum wereo riginally proposed to have diverged from ac ommon ancestor around the same time as their preferred hosts (the divergence of human and chimpanzee lineages): 5-7 Ma.
[ [94] [95] [96] Subsequent molecular clock analyses indicatedt hat P. falciparum is more likely the outcome of am uch more recent transfer, [89] from ag orilla to humans. [97] Thus, ac urrent hypothesisi st hat hominins initially selected for the loss of CMAH were able to escapea na ncestral Neu5Gc-binding pathogen relatedt oP. reichenowi (discussed further below).
Sexual selection through crypticfemalec hoice (female immunity to paternal antigens)
Pathogen-mediated selectiona lone is unlikely to have led to ac omplete fixation of CMAH loss and was more likely as election force for ab alanced polymorphism [98] or even expression polymorphisms, which occur in cats ands ome dogs.
[99] Therefore, as econd mechanism was proposed for fixation:s exual selectiont hrough detection of the Neu5Gc antigen on sperm by antibodies in the CMAH-null female reproductive tract. This hypothesis was tested in female Cmah À/À mice that weres ystemically immunized againstN eu5Gc and had circulating antiNeu5Gca ntibodies. When breeding with male WT mice (whose sperm are decorated with Neu5Gc), am ajor reduction ( % 30 %) in fertility was recorded. [100, 101] It was also shown that human serum with high levels of anti-Neu5GcI gG kills chimpanzee sperm in vitro.
[100] Models of selection based on the frequency and strength of femalei ncompatibility indicated that past an initial frequencyt hreshold, which could have been reached by drift or by pathogen-mediated selection, strong females exual selectionc ould have led to ar apid fixation of the CMAH loss of function mutation. [100] 
AM ouse Model for Human CMAH Loss
Understanding the immediate ramifications of human CMAH is difficult, since our closest genetic ancestors diverged from us % 6Ma [94, 96] and we have since evolvedi ndependently.A lso ethical,l egal and practical issues limit research on chimpanzees. [102] Therefore, a Cmah-null mouse (Cmah À/À )w ith the human-like exon deletion was generatedt op rovideapractical model for studying the immediate loss of CMAH as it would have happened in hominins % 3Ma. Cmah À/À mice have several human-like phenotypes( Ta ble 1), including the induction of anti-Neu5Gc antibodies, [103] enhancement of cancer inflammation and progression of Neu5Gc containing tumors, [104] [105] [106] [107] [108] enhanced immunec learance of recombinantN eu5Gcc ontaining therapeutics, [109] delayeds kin wound healing, [110] enhanced age-related hearing loss, [110, 111] altered immune responses, [112] [113] [114] sexuals election through Neu5Gc antigenicity, [100, 101] altered susceptibility to metabolic disorders, [115] [116] [117] altereds usceptibility to muscular dystrophy, [118] [119] [120] and ax eno-antibody response against the vascular endotheliuma fter nutritional incorporation of Neu5Gc. [121] 6. Biochemical Consequences of CMAH Loss in Humans 6.1. Redox metabolism CMAH oxidoreductase activity requires Fe 2 + and areducing cofactor (NADH or NADPH) for its enzymatic activity. [9] Therefore, disruption of CMAH activity could potentially change redox metabolism, [122] possibly by altering the NAD + :NADHs teady state. Genetic evidence has led to speculationt hat CMAH loss could indirectly lead to increased oxidative damage, [111] and these mechanisms have been proposed to explain gene expression differences observed during changes in metabolism or age-relatedh earing loss observed in Cmah mice. [110, 111, 115, 116] Ad etailed biochemical quantification of NAD + :NADH andR OS levels in relevant Cmah À/À tissues is of major interest, but has not yetbeen performed.
Metabolic incorporation,recycling,and degradation
Although human pseudogenization of CMAH results in ac omplete loss of enzymatic activity, CMAHP is still transcribed, particularly in human stem cells where Neu5Gcu ptake was reported to modulate Wnt/b-catenin signaling. [49] Thus far,t his finding has not been mechanistically explained. This work, along with evidencet hat feeding Neu5Gc to primary human Tcells suppresses their cell proliferation after activation, [113] suggestst hat independent of CMAH oxidoreductase activity, metabolic incorporation of Neu5Gcf rom exogenous sources can affect some cell-signaling processes. More recently, Neu5Gcf eeding has been found to suppress bacterial killing by macrophages from Cmah À/À mice andh umans,w here the expression of the transcription factor C/EBPb was also suppressed. [114] Further studies are neededt os ystematicallye lucidate the possible mechanismsc ontributing to the observed phenotypes( Table 2) .
Free exogenous sialic acids can be taken up by cells through macropinocytosis and transported into the cytosol by the lysosomal transporter sialin, [123] which can be upregulatedi nh ypoxic conditions including in cancer tissue. [124] Thus, the feeding of sialic acid is regulated by endolysosomal transport, which is very different from the feeding of the artificial peracetylated mannosamines that diffuse across cell membranes and can becomeu nnaturally hyper-enriched within the cytosol. [125] Cytosolic sialic acids can then be activated into CMP-Sias and utilized, as if they were endogenously produced. Similarly,e ndogenous cell-surface sialic acids cleaved by the most abundantly expressed endolysosomals ialidase NEU1 experience a similar recycling through the transporter sialin. [123] NEU1-mediated sialic acid catabolism and transportation occur frequently,i no rder to maintain the cell steady state. Furthermore, NEU1 has long been considered the only clinically relevant neuraminidase, as loss of its expression and/or function resultsi nt he lysosomal storage and neurodegenerative disorder sialidosis. [126] However,t here are three other vertebrate sialidases primarily involved in sialic acid catabolism (NEU2-NEU4) that are less abundantly expressed but play significantr oles in many biological functions. NEU2 is cytosolic and highly expressed in muscle, where it is also found in the nucleoplasm. [127] NEU3 is associated with the plasma membrane and primarily targetsc ell-surface gangliosides. NEU4 [128] is associated with intracellular membranes such as the endoplasmicr eticulum and mitochondria. [129] [130] [131] Sialic acids are constantly being cleaved by these host sialidases and reutilized in new glycoconjugates before degradation;t his might explain why the rate of sialic acid turnover is particularly slow in some tissues,s uch as brain. [132] The half-life in normall iver,w here glycansa re primarily protein bound, [19] is % 33 h; [22, 25, 133] however,t he half-life in brain,w here glycans are primarily lipid bound, [19] varies greatly between 4a nd 45 days. [134] Pulsing with Neu5Gc in ah uman B-cell lymphoma cell line yielded a similar half-life ( % 4days) to what has been observed in brain tissue. [135] Although Neu5Aca nd Neu5Gc are handled similarly by enzymeso ft he hexosamineb iosynthetic pathway,t erminal degradationo fN eu5Gc produces glycolate, whereas degradation of Neu5Ac produces acetate [135, 136] (Scheme 2). Thus, once CMAH has converted Neu5Act oN eu5Gc, the acetyl-to-glycolyl conversion is irreversible and potentially affects the metabolic homeostasis of acetate/glycolate ratios in cell metabolism. Since millions of sialic acids are constantly being recycled and degraded within ac ell on ar egular basis so as to maintain as teady state, it's not clear if intracellular acetate, which is quickly converted to acetyl-CoA, [137] drives metabolism in ad ifferentd irection than glycolate, which is converted to oxalate [138] or glyoxylate. [136] Beyond limited gene-expression studies, [111, 116] the true ramificationso ft hesea lteredm etabolic fates duringt he constant degradation to maintain steady state have not been fully explored.
Consequences of CMAH Loss in Humans for Cell Biology
Sialic acids have am ultitude of functions on cell surfaces, such as repulsing other cells, [139] protecting from proteases, [140] and modulating certain cell-signaling pathways. [54, [141] [142] [143] Some areas of interest regarding the ramifications of Neu5Gcl oss on specific cellular processes are discussed below.
Potential biophysical effects
Although the effectso fs ialic acids on cell repulsion and adhesion have been extensively characterized, [19] very little is known about whether the structural differences between Neu5Ac and Neu5Gcc ould alter these processes.
[144] Theoretically,t he loss of Neu5Gc and subsequent loss of millions to tens of millions of hydroxy groups at the terminal cell surface could systemically culminatei ng lobala nd compartmental changes in membrane hydrophobicity between humans and other species (e.g.,m ice and chimpanzees). For example, in "ganglioside patches" [142] or lipid-raft compartments, smallc hanges in interactions involvingNeu5Acversus Neu5Gc are potentially magnified in concentrated compartments or through multivalent interactions. [145] Changes in the partition coefficient of ad rug alters its diffusion rate across membranes, [146] therefore changes in membrane hydrophobicity (through the loss of Neu5Gc) could affect the diffusion of hydrophobic molecules across membranes. Although drug permeability has been studied extensively between species, [147] the effect of human Neu5Gcl oss on drug permeability or the permeability of gasses and molecules that diffuse across cell membranes (such as oxygen and carbon dioxide) [148] has yettob etested.
Changes in Siglec binding
Changesi nt he Neu5Gc/Neu5Ac ratio could potentially alter cell reactivity through changes in the binding of sialic acid ligands to that are complementary receptors, the Siglecs. Siglecs are immunoglobulin superfamily sialic-acid-binding lectins that commonlyi nteract with host sialic acids on immune cells as self-associated molecular patterns (SAMPs) that suppress MAP kinase signaling and subsequent inflammatory responses. [149] This phenomenoni sa lso exploited through Neu5Acs ialic acid mimicryb ym ultiple invading pathogens. [81, 82, 150] Siglecs are rapidly evolvinga nd highly variable across species, [151] thus making it difficult to model human Siglec biology in mice, which have no functional equivalents to human Siglec-5, Siglec-6, Siglec-7, Siglec-11, Siglec-XII, Siglec-13,orS iglec-14.
[152]
Some human Siglecs have also evolvedp articularly rapidly, such as human Siglec-9, which binds both Neu5Aca nd Neu5Gcr elativelye quallyw hereas chimpanzee and gorilla Siglec-9s trongly prefers to bind Neu5Gc. [153] Furthermore, some Siglecs, such as sialoadhesin( Siglec-1) [154] and MAG (Siglec-4) [155] have ac onserved preference from mice to humans for Neu5Ac over Neu5Gc, and it is therefore likely that humanN eu5Gc loss increased their binding and signaling activity. [153] In mice, CD22 (Siglec-2)h as as trongp reference for Neu5Gc.A sC D22 is highly expressed on Bcells (and to al esser degree on Tcells [156] ), loss of inhibitory signaling through the loss of Neu5Gc ligands has been proposed as the mechanism for the B-cell hyper-reactivity observed in Cmah À/À mice. [112, 113, 157] 
Changes in neuraminidase susceptibility
Althoughglycosphingolipids (particularly gangliosides)a ccount for % 80 %o ft he total glycan mass in the brain, [19] neuronal plasticity and development is heavily regulated by very long polysialic acids (PSA) that are primarily ( % 95 %) conjugated to Neural cell adhesion molecule (NCAM) to form NCAM-PSA [158] and catabolized by host neuraminidases. [159] Despitei ts presence in most mammaliant issues, Neu5Gc is present in the brain endothelium but absent from the neuronal brain tissue of all animals tested. [160] One proposed mechanism for this phenomenon is aN EU1 preference fort he a2-8Neu5Ac linkages common in brain polysialic acids [160] [161] [162] over the a2-8Neu5Gc linkages commonly found in fish eggs.
[163] Ar ecent study has shown that Neu5Gc overexpression in the nervous system has multiple detrimental effects, including the loss of the MAG ligand, impaired CNS mylination,i ncreasedP NS degeneration,i mpaired locomotor activity,a nd impaired memory. [162] As eries of studies have implicated endolysosomal NEU1 as am odulator of cell signaling at the cell surface, where it is thought to relocalize and cleave relevants ialic acids under amultitude of different signalingconditions, including the activation of receptor tyrosine kinases and TLRs. [164] [165] [166] As most microbial sialidases have ap reference for Neu5Aco rN eu5Gc and host NEU1 prefers a2-8-linked Neu5Ac over Neu5Gc, it could be that NEU1 has ap reference for the a2-3 or a2-6 Neu5Ac versus Neu5Gcs ialic acidl inkages commonly found on all host cell surfaces. If there is indeed ad ifference, this could potentially contribute towards the differences in signaling observed when feeding Neu5Gc in vitro. [49, 113, 114] Scheme2.Proposed pathway for the metabolic turnover of excess Neu5Gc (including blue moiety)o rNeu5Ac (excluding blue moiety) in mammalianc ells. Neu5Gca nd Neu5Ac are substrates for pyruvate lyase, which forms ManNAc or ManNGc. GlcNAc-2-epimerase (a) potentiallymodifies ManNAc or ManNGc into GlcNAc or GlcNGc, which could then potentially be phosphorylateda tp osition 6b yG lcNAc kinase (b) . Thereafter, the N-acetyl or N-glycolylg roup could be irreversibly removed from GlcNGc-6-P by the GlcNAc-6-P deacetylase (c), which would result in GlcNH 2 -6-P and either acetate or glycolate, which might have different metabolicfates. Modified from ref. [135] ,Copyright 2012:American Society for Biochemistry and Molecular Biology.
Altered cell-surface sialic acid 9-O-acetylation
Another common modification of Neu5Aci s9 -O-acetylation, which can inhibitt he surface recognition of sialic acids by some Siglecs( e.g.,C D22) and certain pathogens, while also preferentially binding other pathogens, such as influenza C. [167] Compared to chimpanzees, humans were found to contain higher levels of cell-surface 9-O-acetylation; [168] this phenomenon is similarly observed in Cmah À/À versusW Tm ice. [110] Although9 -O-acetylation is found to disrupt CD22 (Siglec-2) bindingi nv itro, [169] geneticd eletion in mice leads to the development of auto-antibodies, [157] and more work is needed to determine how secondary changes in surfaceO -acetylation through CMAH loss could contribute to human inflammation and autoimmunity. [170] 
Alterations in cell signaling
Post-translational glycosylationo nBcell, Tcell, andT oll-liker eceptors has been shown to modulate recycling, activation,a nd apoptosis susceptibility throughc lustering or other multivalent interactions. [171, 172] Recent studies have shown the removal or reintroduction of Neu5Gct ob ec apable of modulating adaptive and innate immune cell responsesi nb oth humans and mice. [112, 113, 129, 130, 143, 165, 166, [173] [174] [175] Specific examples of the role of sialic acid in hyper-reactivity are discussed below.
T-cell receptor (TCR) activation:
Compared to chimpanzees tested in captivity,h umans mount ag reater proliferative response to am ultitude of canonical T-cell receptora gonists, including a-TCR antibodies of multiple isotypes, l-phytohemagglutinin (PHA), Staphylococcus aureus super antigen, andasuperagonist a-CD28 Ab, as well as in mixed leukocyte reactions (MLRs). [174, 176] The same phenomenon was observed in Cmah À/À mice compared to WT controls. [113] Although these differences were initially attributed to differences in Siglec expression, suppression of human T-cell proliferation can be achieveds imply by feeding Neu5Gcd uring TCR activation, under conditions under whicht here is no knownd ifference in Siglec expression or Neu5Gc preference. [113] Severalu nanswered questionsa bout the influence of Neu5Gco nT -cell functionr emain, some of which are further discussed in regards to HIV below.
Bcell receptor( BCR) activation:
The BCR forms complexes with multiple glycoproteinsi ncluding Siglec-2 (CD22) and Siglec-G (Siglec-10 in humans) to modulate its threshold of activation.C hronic desensitization through exposure to selfassociated molecular patterns (SAMPs) is of particulari mportance to anergic Bcells to help prevent autoimmunity;t his has been reviewed extensivelye lsewhere. [172, 177] It has been reported that Cmah À/À mice display BCR hyper-reactivity in vivo, [112] which is partially attributed to loss of the CD22 ligand. Furthermore, BCR hyper-reactivity can also occur in human Bcells, [174] which express aS iglec-2 that does not have ap reference for Neu5Aco ver Neu5Gc ligands in vitro. [153] Thus, CD22 preference alone might not explain the hyper-reactivity observed in Bcells, particularly because hyper-reactivity is also observed in human and mouseTcells. [113, 175] 7.5.3. Toll-like receptor 4( TLR4) activation and bacterial killing: Because Cmah À/À mice experience delayed woundh ealing, [110] greater inflammation in some modelso fm usculard ystrophy, [118] and increased growth of transplanted human tumor cells, [104] we investigated the innate immunity of Cmah À/À mousem acrophages and re-examined the dogma that humans and chimpanzeesm ounts imilari nnate inflammatory responses to endotoxin. The resultsw erec onsistentw ith those of previous studies that established that humans and chimpanzees respond at the same order of magnitude to endotoxin. [178] As mall increase in the sensitivity of Cmah À/À mice to endotoxin ex vivo was also observed, with am ore profound effect in vivo. We further investigated af unctional ramification of hyperinflammation (bacterial killing) and found that both Cmah À/ À mice and humans exhibited ag reater capability to kill nonpathogenic bacteria than their WT and chimpanzee counterparts. [114] Thus,i tc an be speculated that human CMAH loss mighth ave been beneficial for clearing minor infections, but could be potentially deleteriousi ns evere infection ande ndotoxic shock.
Physiological Consequences of CMAH Loss in Humans 8.1. Metabolic disorders
Althought he spontaneousd evelopment of type 2d iabetes mellitus (T2DM)h as been reported in apes, [179] it is now an epidemic (along with obesity) in unhealthy humans,a nd am ajor pathological consequence of diabetes is pancreatic islet b-cell loss due to apoptosis. [180] It hasb een reported that Cmah À/À mice might experience an altered glucosem etabolism at baseline [116] and after consumption of ah igh fat diet. [115, 117] Impairment of glucose metabolism after ah igh-fat diet in Cmah À/À mice was attributed to pancreatic b-cell failure rather than insulin resistance, as determined from the reduced pancreatic islet area. [115] Subsequently,W Ta nd Cmah À/À true littermate controlsw ere independently examined under different conditions. [117] Althoughadetailed quantification was not reported, ar eduction in both pancreatic islet size and b-cell number was independently observed in Cmah À/À mice compared to WT controls. [117] Thus, Cmah À/À might have smaller pancreatic islets and reduced b-cells;t his is interesting because human pancreatic islets are smaller than monkeys' [181] and contain fewer b-cells (and more a-cells) compared to rodents' andm ost nonhuman primates'. [182] Ad eeper investigation (including ad etailed quantification of WT versus Cmah À/À pancreatic islets) into littermate controls under normal-andh igh-fat-diet conditions is necessary to further determine the effects of Cmah inactivity on islet cell distribution and glucose homeostasis. Thus, the role of Neu5Gcl oss in susceptibility to diabetesm ellitus remains to be clearly determined.
Delayed woundhealing
It has been reportedt hat Cmah À/À experience delayeds kinwound healing, [110] with no obviousd ifferences in immune cell ChemBioChem 2017 ChemBioChem , 18,1 155 -1171 www.chembiochem.org 2017 Wiley-VCH Verlag GmbH &Co. KGaA, Weinheim recruitment, angiogenesis, or keratinocyte morphologyr eported. There has never been af ollow-up study,a nd the mechanisms involved in this phenotype have never been characterized or described.I tc ould be speculated that the redox and/or macrophage changes mentioned before might be involved.
Age-related hearing loss
By nine months of age, Cmah À/À mice display reduced hearing sensitivity across all frequencies, increased outer-hair-cell degeneration throughout the cochlea, and collapse of the outer organ of Corti compared to WT controls. [110] This phenotype has been independently confirmed, [111] but the biochemical mechanisms involved have yet to be characterized or described.
Gut microbiome
The human body harbors trillions of microbes in the gastrointestinal (GI) tract [183] that are proposed to influence virtually every aspecto fh uman health,i ncluding immune cell function, [184] metabolic disorders, [185] neurodegeneration, [186] and cancer. [187] Many gut microbes, including pathogenic types, have developed the ability to use host sialica cids as an energy source in multiple ways, either throughc leavage and/ors cavenging with subsequentd ifferentialt ransport capabilities. [83, 188] Although the sialic acid synthesis and neuraminidase preferences of many bacteria have been studied in relation to the host-pathogen interface, whether these individual microbes prefer Neu5Gc overN eu5Ac as an energy source in culture or within the intestine remains an open question to be explored in WT and Cmah À/À mice.
Pathological Consequences of CMAH Loss in Humans 9.1 Antibodyp roduction and antigenicity
All humans who have consumed Neu5Gc express variable levels of circulating anti-Neu5Gc antibodies. The antigenicity of humans against Neu5Gc is not inherited from the mother, rather it has been attributed to its cell-surface presentation by common commensal bacteria (e.g., Haemophilus influenza) after consumption of Neu5Gc after birth, [52, 103] potentially coinciding with the introduction of cow based infant formula and baby food. Thus, all humans who continuet oc onsume Neu5Gcc ould experience" xenosialitis", the host response to af oreignb ut metabolically tolerated antigen (reviewed extensively elsewhere). [54, 55, 58, 189] Briefly,r ed meat is particularly high in Neu5Gcc ompared to poultry and fish, which contain low or undetectable Neu5Gcc ontent (with the exceptiono fc aviar). [108, 190] When Neu5Gc-rich food is consumed,i ti sa bsorbed and either eliminated in urine or metabolically incorporated into somet issues. [52, 191] The display of this foreign antigen induces an immune response through antibody-and complement-mediated xeno-autoantigeni mmunity.C hronic inflammation induced in this way was recently shown to increase the propensity for carcinomaf ormation in the Cmah À/À mouse. [108] In this regard, Neu5Gch as been reported for decades as a potentiala ntigen in multiple cancerp athologies including lung, [51] liver, [51, 192] colon, [47, 51, 193] kidney, [194] breast, [50, 52, 195] skin, [195] [196] [197] ovary, [197] and throat [198] cancers as well as malignant lymphoma. [51] Although nutritional incorporationa lone does not lead to anti-Neu5Gci mmunization in Cmah À/À mice, antiNeu5Gci mmunization is achieved by co-stimulation through injectionw ith chimpanzee red blood cells (RBCs) or with Neu5Gc-containingt umor cell lines. [103] Cmah À/À mousea ntiNeu5Gc antibody production has become an important model for the study of Neu5Gca ntigenicity in humans. [54, 55, 58, 189] AntiNeu5Gca ntibodies have been directly shown to enhance tumor growth in Cmah À/À mice by promoting cancer-associated inflammation [104, 108] and anti-Neu5Gca ntibodies have been identified as potentials erum biomarkers for tumors in humans. [107] The possibility that higherl evels of antibodies might be tumoricidal needs further study,a sa nti-Neu5Gc passively transferred into mice bearing as yngeneic MC-38 colon adenocarcinoma display ah ormetic relationship between tumorg rowth and antibody dose. [105, 106] The potentiale ffects of anti-Neu5Gc antibodies on thev ascular endothelium have been modeledi nv itro but have yet to be described in vivo. [121] Neu5Gc aggregates have also been found in dystrophic humana nd Cmah À/À mouse muscle tissue, [120] but the implications of this are not yet fully understood.
Infectious diseases
Infectious diseases remain am ajor cause of death,d isability, and suffering for hundreds of millions of peoplet hroughout the world. [199] Many pathogens and toxins bind specific linkages of sialic acids, [200] and some major human-specific pathogens have been found to prefer Neu5Aco ver Neu5Gc linkages. Multiple infectious diseasep athologies are further complicated by an apparently hyperactive immune system associated with Neu5Gc loss. Some examples are described below.
9.2.1. Malaria: The most common and most severe form of malaria parasite in humans is P. falciparum. The meorozoite stage contains a1 75 kDa erythrocyte-binding protein (EBA-175) that binds sialic acid residues on glycophorin Ad uring invasion of the erythrocyte. It was demonstrated that EBA-175 binds human RBCs better than chimpanzee RBCs and that Neu5Gcf eeding could suppress the EBA-175 binding to a human erythroleukemia line. [90] In contrast, EBA-175 from the chimpanzee parasite P. reichenowi strongly prefers Neu5Gc, and this difference in binding preference could account for the difference in species infectivity observedb etween P. falciparum and P. reichenowi for humans and chimpanzees. Furthermore, primary RBCs from New World monkeys, which also lack cellsurfaceN eu5Gc, also showed as imilar susceptibility to EBA-175 binding to human RBCs. [90] Ta ken together,these data illustrate ah uman Neu5Ac binding specificity for P. falciparum EBA-175 protein. Whether or not P. falciparum has binding preferences for WT versus Cmah À/À mouseR BCs has yet to be quantified. [201] Historically,t he 1918 flu pandemic killed more peoplet han the entire First World War. [202] Influenza virus strains are nameda fter their surface glycoproteinsh emagglutinin (H) and neuraminidase (N;e .g.,H 1N1), which bind and cleave sialic acids, respectively.I nfluenza type Ah emagglutinin was the first microbial hemagglutinin ever described, [203] and its hosts pecificity is dependentu pon its sialic acid linkage preference. [84] For example, human influenzat ype Ah emagglutinin preferentially binds a2-6-linkeds ialic acids (Neu5Ac), whereas avian influenzah emagglutinin preferentially binds a2-3-linked sialic acid. [204, 205] Alterationsinh emagglutinin binding specificity from a2-3 to a2-6 or from Neu5Act oN eu5Gc can be achieved throughm inor amino acids ubstitutions. [206, 207] InfluenzaN eu5Ac or Neu5Gc binding preferencesa re also species dependent. For example, the horse tracheae xpresses % 90 %N eu5Gc, and some equine influenza types prefer Neu5Gcf or invasiona nd replication. [208] Swine tracheaea re % 50 %N eu5Gc, and swine influenzat ypes can vary between Neu5Aco rN eu5Gc preference. [209] Interestingly,s ome human influenzas trains are still capable of binding Neu5Gc, [206] yet Neu5Gcf eeding hasa lso been found to suppress human epithelial cell infectivity in influenzat ype As trains with Neu5Gc bindingc apability. [210] Thus, both sialic acid linkage and sialic acid type affect the infectivity of influenza viruses in as peciesspecific manner,a nd animals with similar airway sialic acid architecture to humans, such as ferrets, who also lack afunctional CMAH (see below), are also susceptible to the airbornet ransmission of human influenza. [86] 9.2.2.2. Humani mmunodeficiencyv irus:H umani mmunodeficiency virus (HIV) is ar etrovirus that continues to infect and kill millions of people every year,p articularly in regionso f socio-economic disparity. [211] Although chimpanzees suffer from an AIDS-like SIVcpz immunopathology, [212] HIV progression to AIDS occurs more frequently and is more severe in humans compared to chimpanzees. [41, 213, 214] The causative mechanisms for this have never been unequivocally determined. HIV,t he HIV envelope proteinsg p120 and gp41, and the HIV gag protein p24 elicit as trong proliferative response in chimpanzee lymphocytes,e ven after years of HIV infection. [213] Conversely, human lymphocyte proliferative responses to HIV are relatively impairedc ompared to chimpanzee lymphocytes [215] and this has been proposed as am echanism of human AIDS susceptibility. [213] Othersh ave proposed that human AIDS is attributed to ag reater susceptibility of lymphocytes to apoptosis, [216, 217] potentially through differential expression of Siglecs. [176, 217] AlthoughN eu5Gc feeding alone is capable of altering T-cell proliferation after TCR activation, [113] whether or not Neu5Gc feeding can alter the susceptibility to apoptosis in these systems is of interest, but has not yet been systematically explored. It is also notable that Siglec-1, which initiates formation of the virus-containing compartment and enhances macrophage-toTcell transmission of HIV-1, [218] has av ery strongp reference for recognizing Neu5Aco ver Neu5Gc. Siglec-1 also shows increasedpositivity and altered distribution in humans compared with chimpanzees. [153] 9.2.3 Susceptibility to bacterial infections 9.2.3.1. Streptococcus pneumoniae: S. pneumoniae infections cause % 11 %o fa ll deaths among children up to 5y ears old [219] and are the major cause of community-acquired pneumonia in the elderly. [220] Like many other sialic-acid-utilizing pathogens, S. pneumoniae expresses an euraminidase (nanA) and as ialic acid transporter (SatABC) that together are capable of harvesting and taking up sialic acids from host mucins and other glycoconjugatesi nt he nasopharynx. Interestingly, S. pneumoniae TIGR4 (serotype 4) has evolvedt or espond preferentially to Neu5Ac over Neu5Gc under conditions of low glucose (e.g., nasopharynx)w ith ap ositive feedback loop, upregulating both nanA and htrA, whichp rotects from oxidative stress. This phenomenonm ight ultimately explain why Cmah À/À mice experience af aster pneumococcal disease progression after intranasal but not intravenous challenge. [221] 9.2.3.2. Typhoid fever: Salmonella enterica serovar typhi (S. typhi)i sahuman-specific pathogen that continues to infect tens of millions and kill hundredso ft housands every year,p articularly children who live in regions of poor sanitation and lack access to clean food or water. [222] Although S. typhi is not capable of infecting mice, am ouse model that preferentially binds Neu5Acw as developedb yi njectionw ith typhoid toxin. [223] Thus, typhoid toxin can produce typhoid fever symptoms in WT mice, but not in transgenic micet hat overexpress Cmah ( % 98 %N eu5Gco na ll tissues). [87] Although this does not explain why humans and chimpanzeesd evelop typhoidi nfection after consumption of S. typhi, it might help explain why humans experience am ore severe form of typhoidf ever than chimpanzees.
[33] 9.2.3.3. SubAB toxins:S higa toxigenic Escherichia coli (STEC) is ac ommon food-borne pathogen [224] that can cause serious diseases,i ncluding bloody diarrhea, and sometimes hemolyticuremic syndrome (HUS). STEC secretes aS ubAB toxin that was found to preferentially bind Neu5Gci nv itro and ex vivo. Althought he metabolic introduction of Neu5Gc into human cell lines increased susceptibility to SubAB toxicity,i nfection of Cmah À/À mice resulted in af aster disease progression than in WT controls. This was found to be due in part to al ack of competitive inhibition of serum proteins in Cmah À/À mice. [93] Regardless,o wing to its Neu5Gcb inding preference, humans who consume red meats rich in Neu5Gcm ight incorporate it into their gut epitheliuma nd this can allow for toxicityo fa subsequentSubAB-positive infection.
[225]
Muscular Dystrophy
In humans,D uchenne musculard ystrophy (DMD) is the most common and most severe musculard ystrophy affecting children. [226, 227] Concerted efforts towards the development of new practical therapeutics (gene-and cell-based therapies) have resulted in many new promising paradigms, some on the forefront of clinical utilization. [227, 228] But until recently,acriticalbarrier to progressi nt he field has been the stark difference in the severity of the musculard ystrophy observed between mice and humans, [229] with mice showing minimal phenotypes. However, Cmah À/À mice experience ap rofound increase in DMD and limb-girdle musculard ystrophy 2D (LGMD2D) severity, most notably in DMD life expectancy. [118] [119] [120] Cmah À/À /mdx mice experience greater musclew eakness, greaters keletal muscle fibrosis,g reater immune cell recruitment to both the cardiac and skeletal muscle tissue, more inflammatoryc ytokine productioni ns keletal muscle, and decreased survival compared to WT/mdx controls. [118] [119] [120] Further work is needed to determine whether this difference should be attributed to an intrinsic difference in musclep hysiology,t he adaptive immune system,a nd/ort he innate immune system.T his could be tested by HSA-Cre (muscle), CD4-Cre (T-cells of the adaptive immune system), or CD14-Cre (innatei mmunes ystem) expression of Cmah in Cmah À/À /mdx mice, buts uch experiments have yet to be reported. Besides an apparent increase in Neu5Gcv ersus Neu5Aca ffinity for a-laminin in vitro, [118] the underlying mechanisms responsible for this phenomenona re completely unknown, and it is possible that "xenosialitis" could be an aggravating factor. [120] Understanding thesem echanisms could reveal new therapeutic targets that are possibly beneficial to the human lineage. They could also help us to understand what has set humanm uscle tissue apart from mouse and chimpanzee muscle tissues, whicha re both relatively high in Neu5Gc. [120] 
Evolutionary Implications of Human CMAH Loss
Although sexual and microbial selection might have led to the fixation of CMAHP,s ubsequentc hanges in systemic inflammation and metabolism could have benefited ancient hominins transitioning towards exposure to new pathogen regimes during the transition from forests to open savannahs, to an increasedc onsumption of other animals, and the earliest developments of stone toolu se. [64-66, 79, 114, 230] The definite evolutionary cost of CMAH loss is at least twofold:f irst, the inability to modulate the ratio of Neu5Gca nd Neu5Ac in the glycocalyx of varioust issues and their secretions, and second, the inability to use the presence of abundantN eu5Gc as an honesta nd costly signal of self. [231] 11.O ther Medical ImplicationsofCMAH Loss in Humans 11.1. Xenotransplantation Humans, apes, and Old World monkeysa lso lack at erminal agalactose (a-gal) residue, which is am ajor antigen (along with Neu5Gc) causingh yperacuter ejection after xenotransplantation in humans or decreased half-life in animal-based transplantations.
[232] To address this, pigs lacking a-gal [233] or both agal and Neu5Gc [234] were created so as to decreaset he immunogenicity of pig xenografts-with some success.
[235] Indeed, this work confirmed that, in their bound form (e.g.,i nt issue), both a-gala nd Neu5Gc are major foreign antigenst hat trigger inflammation and contribute to tissuer ejection. [236] Ongoing studies are seekingt os ystematicallyi mprove potential sources of tissue for xenotransplantation.
[237]
Stem cells and recombinant proteins
Nutritionally,t here is am ajor difference in immunogenicity between Neu5Gca nd a-gal that occurs during catabolism, during which a-gal becomes free galactose (and is further utilized normally), but free Neu5Gci si ncorporated and presented on host cell surfaces as the same bound foreign antigen. [58, 238] Therefore, all glycosylatedh uman cells and recombinantp roteins grown in the presence of serum from other animals or on mousef eeder cells are potentially contaminated with the cell-surface antigen Neu5Gc;t his potentially causes rapid clearance from circulation [109] and/ort riggersa na ntibody-mediated inflammatory response. [49, 109, 239] 
Independent CMAH Loss in Other Taxa
Since the originald iscovery of human-specific Old World primate CMAH loss, monotremes(platypus), sauropsids (birds and reptiles), pinnipeds (walruses,s ea lions and seals), mustelids (ferrets), and platyrrhines (New World monkeys)h ave all been shownt oh ave independently lost or inactivated CMAHa nd the endogenous production of Neu5Gc. [86, 240] Similarly to humans, [205] ferrets express high levels of a2-6-linked Sias in their airway epithelium, which,a long with Neu5Gc loss, explains their successful use as am odel for human influenza infections. [86] Interestingly,N ew World monkeys are the only other primatesk nown to lackN eu5Gc and are the standard model for P. falciparum infection in vivo. [90, 241] Further field studies are necessary to determine whether New World monkeys are potentially ar eservoir for human P. falciparum infection in the wild. [242] 
Summary and Outlook
Due to the high prevalence of sialic acids on all cell surfaces, the loss of CMAH in the hominin lineage likely had complex physiological ramifications, as evident in the multiple organ and cell types affected in Cmah mice. Many of these phenotypic differences observed between WT and Cmah À/À mice are possibly analogoust od ifferencesb etween humans and chimpanzees,b ut much more work is neededt ou nderstandt he many mechanisms likely to be at play.I mportantly,t hese mechanisms could have implications for the treatment of diseases specifically affecting humans, such as musculard ystrophy,t hat are difficult to model in rodents. Exogenously,m any deadly human pathogens have aN eu5Acp reference and possibly al inkage-specific preference contributing to their speciesspecific infectivity,a si st he case with influenza. Furthermore, many pathogens, commensal bacteria, and/or symbiotic bacteria, such as S. pneumoniae,m ight have an optimal metabolic preference for Neu5Aco ver Neu5Gc. Many of these and other questionsa bout human sialic acid biology remainu nexplored or unreported.T he hope is that these studies will highlight the 
